Sanofi may seek higher European drug prices, not withhold launches, under Trump deal
While some of Europe’s biggest drugmakers have warned that President Donald Trump’s pricing policies could leave European patients waiting …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
For Lilly, cash-pay is key in the US and, increasingly, abroad October 29, 2026
R&D chief Dean Li says Merck outflanked rivals with its sac-TMT cancer program October 29, 2026
Updated: Lilly beats revenue forecasts, lifting full-year outlook for third straight quarter October 29, 2026
After Be Bio shutdown, its CEO heads to Orbis; Enanta's longtime chief Jay Luly to retire
AstraZeneca says reorg could mean R&D cuts and trials shifted to emerging markets
Sanofi has no plans for a 'major' overhaul as Dupixent's patent cliff looms
Setara gets $90M to continue rare disease pipeline spun out of Jazz's Actio deal
Source link







